We are live on
!
Find out more
FA
Forefront Analytics Portfolio holdings
AUM
$92M
1-Year Est. Return
25.18%
This Fund
S&P 500
This Quarter
Est. Return
+1.25%
1 Year Est. Return
+25.18%
3 Year Est. Return
+50.89%
5 Year Est. Return
+36.12%
10 Year Est. Return
–
AUM
$175M
AUM Growth
-$18.7M
(-9.6%)
Cap. Flow
-$20.4M
Cap. Flow
% of AUM
-11.66%
Top 10 Holdings %
Top 10 Hldgs %
62.95%
Holding
80
New
1
Increased
22
Reduced
41
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares ESG Aware MSCI EAFE ETF
ESGD
|
+$5.7M |
| 2 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$116K |
| 3 |
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
|
+$86.8K |
| 4 |
Pfizer
PFE
|
+$64.7K |
| 5 |
Jasper Therapeutics
JSPR
|
+$58.1K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nuveen ESG Large-Cap Value ETF
NULV
|
+$6.37M |
| 2 |
iShares Gold Trust
IAU
|
+$1.75M |
| 3 |
Xtrackers MSCI EAFE Hedged Equity ETF
DBEF
|
+$1.6M |
| 4 |
First Trust North American Energy Infrastructure Fund
EMLP
|
+$1.53M |
| 5 |
iShares Core S&P 500 ETF
IVV
|
+$1.41M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 97.74% |
| 2 | Healthcare | 1.3% |
| 3 | Technology | 0.42% |
| 4 | Financials | 0.29% |
| 5 | Industrials | 0.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Regeneron Pharmaceuticals
REGN
$85.6B
| $245K | 0.14% |
341
-16
| -4% | -$12.3K |
|
52
Thermo Fisher Scientific
TMO
$226B
| $223K | 0.13% |
427
-48
| -10% | -$25.9K |
|
53
Incyte
INCY
$25.9B
| $220K | 0.13% |
3,533
+8
| +0.2% | +$535 |
|
54
Medtronic
MDT
$121B
| $214K | 0.12% |
2,431
-853
| -26% | -$73.4K |
|
|
MREO
55
Mereo BioPharma
MREO
$41.5M
| $109K | 0.06% |
82,749
-951
| -1% | -$1.1K |
|
|
56
Jasper Therapeutics
JSPR
$22.8M
| $95K | 0.05% |
6,937
+3,908
| +129% | +$58.1K |
|
57
Annexon
ANNX
$921M
| $94.3K | 0.05% |
26,790
+11,539
| +76% | +$50.4K |
|
|
FUSN
58
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $93.8K | 0.05% |
+20,075
| New | +$86.8K |
|
59
CytomX Therapeutics
CTMX
$791M
| $85.3K | 0.05% |
49,596
+23,184
| +88% | +$38.5K |
|
|
ACHL
60
DELISTED
Achilles Therapeutics
ACHL
| $70.7K | 0.04% |
74,769
-856
| -1% | -$813 |
|
|
KRON
61
DELISTED
Kronos Bio
KRON
| $67.2K | 0.04% |
39,068
-227
| -0.6% | -$360 |
|
|
LONA
62
LeonaBio Inc
LONA
$72.5M
| $61.4K | 0.04% |
2,081
-82
| -4% | -$2.34K |
|
63
Geron
GERN
$977M
| $47.8K | 0.03% |
14,891
-12,691
| -46% | -$36.1K |
|
|
PSTX
64
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $46.9K | 0.03% |
26,619
+11,579
| +77% | +$29.6K |
|
65
Nkarta
NKTX
$208M
| $22.7K | 0.01% |
10,367
-108
| -1% | -$475 |
|
66
Abbott
ABT
$189B
| – | – |
-3,009
| Closed | -$305K |
|
67
ALX Oncology
ALXO
$279M
| – | – |
-13,037
| Closed | -$58.9K |
|
68
Invesco DB Commodity Index Tracking Fund
DBC
$1.89B
| – | – |
-13,343
| Closed | -$317K |
|
69
Invesco DB Agriculture Fund
DBA
$1.25B
| – | – |
-40,111
| Closed | -$819K |
|
70
iShares MSCI Emerging Markets ETF
EEM
$31.8B
| – | – |
-7,748
| Closed | -$306K |
|
71
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
$16.3B
| – | – |
-2,948
| Closed | -$223K |
|
|
72
iShares Gold Trust
IAU
$65.6B
| – | – |
-46,743
| Closed | -$1.75M |
|
|
73
Nuveen ESG Large-Cap Value ETF
NULV
$2.54B
| – | – |
-187,045
| Closed | -$6.37M |
|
74
Philips
PHG
$25.4B
| – | – |
-11,679
| Closed | -$184K |
|
75
State Street Energy Select Sector SPDR ETF
XLE
$41.7B
| – | – |
-12,240
| Closed | -$507K |
|
Similar funds
VI
GBA
PBCM
HI
DCA
SWP
SAM
Forefront Analytics's Q2 2023 Portfolio in Review
As of Q2 2023, Forefront Analytics held 80 positions worth $175M, down 9.6% from $194M the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Forefront Analytics withdrew a net $20.4M in Q2 2023, closing 15 positions and reducing 41 holdings. Its most notable exit was Nuveen ESG Large-Cap Value ETF, an estimated $6.37M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 98% of assets, up from 98% a quarter earlier, followed by Healthcare and Technology.
Against the trend, Forefront Analytics opened a new position in Fusion Pharmaceuticals Inc. Common Shares worth $93.8K.
- Forefront Analytics's largest Q2 2023 buy was Fusion Pharmaceuticals Inc. Common Shares: 20,075 shares worth $93.8K.
- Forefront Analytics added most to iShares ESG Aware MSCI EAFE ETF in Q2 2023, an estimated $5.7M increase.
- Forefront Analytics's biggest Q2 2023 reduction was Xtrackers MSCI EAFE Hedged Equity ETF, cutting an estimated $1.6M.
- Forefront Analytics fully exited Nuveen ESG Large-Cap Value ETF in Q2 2023, selling an estimated $6.37M.
- Forefront Analytics's ten largest holdings make up 63% of its $175M portfolio in Q2 2023.
- Forefront Analytics opened 1 new position and closed 15 in Q2 2023.
- Forefront Analytics's portfolio value fell 9.6% quarter-over-quarter to $175M.
Based on Forefront Analytics's 13F filing for Q2 2023, filed 11 Aug 2023.